New LOGO Comes on Stage: Amoytop Biotech Improves Its Brand Image.
On January 17, Tebao Biotech held a brand image upgrade launch ceremony in Xiamen. The company's brand visual image was fully refreshed and upgraded, and a new brand LOGO and brand upgrade promotional video were released, marking the official launch of Tebao Biotech's new brand development strategy.
On January 17, Tebao Biotech held a brand image upgrade launch ceremony in Xiamen. The company's brand visual image was fully refreshed and upgraded, and a new brand LOGO and brand upgrade promotional video were released, marking the official launch of Tebao Biotech's new brand development strategy.
READ MORELaunch of New Product-Pegneugen (Telpegfilgrastim Injection)
Xiamen, China, July 1, 2023/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop Biotech hereinafter) today announced that Pegneugen® (Telpegfilgrastim Injection) has been approved by National Medical Products Administration (NMPA) and is available for marketing.
Xiamen, China, July 1, 2023/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop Biotech hereinafter) today announced that Pegneugen® (Telpegfilgrastim Injection) has been approved by National Medical Products Administration (NMPA) and is available for marketing.
READ MOREOn October 19, Hu Zucai, counselor of the State Council and former deputy director of the National Development and Reform Commission, accompanied by leaders of the governments of Fujian Province, Xiamen City and Haicang District, visited Tebao Biotech for investigation. Sun Li, chairman and general manager of Tebao Biotech, received the visiting leaders and gave a detailed report on the company's production, operation and development plans, and focused on the role of Pegbin (long-acting interferon) in improving the clinical cure rate of hepatitis B and reducing the risk of liver cancer. research progress in this regard.
On October 19, Hu Zucai, counselor of the State Council and former deputy director of the National Development and Reform Commission, accompanied by leaders of the governments of Fujian Province, Xiamen City and Haicang District, visited Tebao Biotech for investigation. Sun Li, chairman and general manager of Tebao Biotech, received the visiting leaders and gave a detailed report on the company's production, operation and development plans, and focused on the role of Pegbin (long-acting interferon) in improving the clinical cure rate of hepatitis B and reducing the risk of liver cancer. research progress in this regard.
READ MOREAmoytop's Quality Center awarded CNAS certificate
Recently, Amoytop's Quality Center was awarded the certificate issued by China National Accreditation Service for Conformity Assessment (CNAS) (Certificate number: CNAS L4479).
Recently, Amoytop's Quality Center was awarded the certificate issued by China National Accreditation Service for Conformity Assessment (CNAS) (Certificate number: CNAS L4479).
READ MORE